Salmeterol xinafoate
SIGMA/S5068 - ≥98% (HPLC), solid
Synonym: (±) 4-
CAS Number: 94749-08-3
Empirical Formula (Hill Notation): C25H37NO4 · C11H8O3
Molecular Weight: 603.75
MDL Number: MFCD00897708
Linear Formula: C25H37NO4 · C11H8O3
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white |
| form | solid |
| InChI | 1S/C25H37NO4.C11H8O3/c27- |
| InChI key | XTZNCVSCVHTPAI-UHFFFAOYSA |
| originator | GlaxoSmithKline |
| Quality Level | 100 ![]() |
| SMILES string | OC(=O)c1ccc2ccccc2c1O.OCc |
| solubility | ethanol: slightly soluble |
| H2O: slightly soluble | |
| methanol: freely soluble |
| Application: | Salmeterol xinafoate was used as conjugate with human serum albumin to study the immune responses in rabbits.7 |
| Biochem/physiol Actions: | β2-adrenoceptor agonist. |
| Biochem/physiol Actions: | Salmeterol xinafoate is a β2 adrenoceptor agonist with longer lasting bronchodilation and anti-inflammatory effects. It relaxes the airway smooth muscles, stabilizes mast cells and regulates the release of histamine. Salmetrol is particularly effective in treatment of mild asthma, chronic obstructive pulmonary disorder.5,6 |
| Features and Benefits: | This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 10, 50 mg in glass insert |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| UNSPSC | 12352200 |

